Business Wire

IFF Announces Further Evolution of its Board of Directors

27.2.2023 14:55:00 EET | Business Wire | Press release

Share

IFF (NYSE: IFF) today announced the next phase of the evolution of its Board of Directors, to support the ongoing execution of the company’s strategic transformation and long-term financial vision.

Kevin O’Byrne, Chief Financial Officer and director of J Sainsbury Plc, has been appointed to join the IFF Board, effective March 10, 2023. O’Byrne is an established financial executive with decades of experience driving sustainable growth and overseeing transformation strategies for international consumer retail businesses. He brings to IFF a deep understanding of the consumer landscape and evolving expectations of CPG customers, which will be valuable to IFF as it continues to execute on its customer-centric and growth-focused strategy. O’Byrne will serve on the Board’s Audit, Innovation, and Transaction Committees.

IFF also announced that Edward (Ed) Breen and Matthias Heinzel, both of whom have served as directors and members of the Board’s Innovation Committee since 2021, have notified IFF of their respective decisions to retire from the Board. Breen and Heinzel will not stand for reelection at IFF’s 2023 Annual Meeting of Shareholders. In addition, Stephen Williamson, director since 2017 and a member of the Board’s Audit Committee, has notified IFF of his decision to retire from the Board effective March 10, 2023.

“On behalf of the entire Board, I would like to thank Ed, Stephen and Matthias for their many contributions to IFF,” said Dale Morrison, Chair of the IFF Board. “As directors, each has helped oversee the development of IFF’s refreshed growth strategy as we’ve become an even stronger partner for customers across the global value chain for consumer goods and commercial products. It has been an honor to work alongside these three leaders and I wish them all the best in their next chapters.”

“It has been a privilege to serve on the IFF Board as the company has established itself as the industry’s premier partner through the transformative combination of DuPont’s Nutrition and Biosciences business,” said Ed Breen, Director of the IFF Board. “Both the IFF Board and leadership team have taken strong action to position the company for long-term profitable growth and significant value creation, and I look forward to seeing all that IFF will accomplish in the future.”

“As we continue to evolve our Board of Directors, I am thrilled to welcome Kevin as an incoming director,” said Roger Ferguson, Incoming Chair of the IFF Board. “Kevin brings more than 30 years of retail and consumer goods experience to the IFF Board and a proven track record overseeing numerous multinational finance initiatives and successful business integrations. I am confident that his expertise and international perspective will be critical as we capture new growth opportunities, execute on our productivity initiatives and optimize our portfolio.”

O’Byrne is responsible for the finance, strategy, property, procurement and investor relations functions at J Sainsbury Plc, the second largest retailer in the United Kingdom. He will be retiring from Sainsbury's on March 4, 2023. Prior to joining J Sainsbury Plc, he served as Chief Executive Officer of Poundland Group Plc and held various leadership positions at Kingfisher Plc, including Divisional Director UK, China and Turkey, as well as Chief Executive Officer of B&Q UK & Ireland and Group Finance Director.

O’Byrne sits on the Board of Centrica Plc, the leading energy supply and in-home servicing provider in the UK and Ireland. He has chaired the Audit and Risk Committee since May 2019 and is the Senior Independent Director (SID). O’Byrne sat on the board of Land Securities Group Plc, the UK’s largest listed real estate group, for nine years where he chaired the Audit Committee and was SID.

“I am thrilled to join the IFF Board during such an exciting time for the company,” said Kevin O’Byrne, Incoming IFF Director. “IFF continues to lead the industry in delivering innovative solutions that meet the needs of today’s customers, and the company has a clear opportunity to realize its full potential. I look forward to partnering with Roger and the rest of the Board to help IFF become an even stronger industry leader, while driving sustainable, profitable growth.”

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i

Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release

Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye